William H. Carson Acquires 3,200 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) Director William H. Carson acquired 3,200 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was acquired at an average cost of $5.48 per share, with a total value of $17,536.00. Following the completion of the acquisition, the director now owns 19,200 shares in the company, valued at approximately $105,216. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Annexon Price Performance

Shares of Annexon stock opened at $5.82 on Friday. The company has a 50 day simple moving average of $5.66 and a two-hundred day simple moving average of $5.48. The firm has a market cap of $537.84 million, a PE ratio of -3.96 and a beta of 1.28. Annexon, Inc. has a 1 year low of $1.57 and a 1 year high of $8.40.

Annexon (NASDAQ:ANNX) last announced its earnings results on Monday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). As a group, research analysts anticipate that Annexon, Inc. will post -0.97 earnings per share for the current year.

Hedge Funds Weigh In On Annexon

Hedge funds and other institutional investors have recently modified their holdings of the company. Bain Capital Life Sciences Investors LLC boosted its stake in Annexon by 8.0% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 8,703,268 shares of the company’s stock worth $62,402,000 after buying an additional 641,549 shares in the last quarter. BVF Inc. IL purchased a new stake in shares of Annexon in the 4th quarter valued at $31,780,000. Point72 Asset Management L.P. grew its holdings in shares of Annexon by 16.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 5,989,017 shares of the company’s stock valued at $29,346,000 after purchasing an additional 832,617 shares during the last quarter. Vanguard Group Inc. raised its position in Annexon by 96.4% in the 1st quarter. Vanguard Group Inc. now owns 3,747,655 shares of the company’s stock worth $26,871,000 after purchasing an additional 1,839,329 shares during the period. Finally, Bellevue Group AG bought a new stake in Annexon in the first quarter worth $15,647,000.

Wall Street Analyst Weigh In

Several research firms have issued reports on ANNX. Wells Fargo & Company dropped their target price on Annexon from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a report on Wednesday, June 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Annexon in a report on Tuesday, August 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Annexon in a research report on Tuesday, August 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $15.80.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.